Document is current
Any future updates will be listed below
-
Authors
Xin, Yingying
Gao, Liuliu
Li, Sichan
Wang, Jun
Chen, Chen
Tuo, Yali
Nie, Gang
Li, Ruizhen
Sun, Dan
Fu, Yongli
Wang, Yang
Liu, Zhisheng
-
Funding
Funding for this research was provided by:
The medical research project of Wuhan Municipal Health Commission (WX21A14, WX21A14, WX21A14, WX21A14, WX21A14, WX21A14, WX21A14, WX21A14)
National Key Research and Development Plan (2016YFC1306202, 2016YFC1306202)
Hubei Provincial Science and Technology Plan Project for Clinical Research Center of Neurodevelopmental Disorders in Children (No. 2022DCC020, No. 2022DCC020, No. 2022DCC020)
Health commission of Hubei Province scientific research project (WJ2019H426)
- License Information
-
More Information
Article History
Received: 12 May 2024
Accepted: 6 June 2025
First Online: 2 July 2025
Declarations
:
: The study was approved by the Ethics Committee of Wuhan Children’s hospital, Huazhong University of Science and Technology (No: 2021R101-E01), Informed consent was obtained from the guardians of the children involved in this study which was in accordance with the Declaration of Helsinki and the Ethical Review Methods for Biomedical Research involving Humans adopted by the National Health and Family Planning Commission of the People’s Republic of China. This research was registered in China National Medical Research Registration and Filing Information System, the Clinical Trial Number is MR-42-21-015866(Quantitative pharmacological study on drugs for treating the neurodevelopmental disorders).
: The authors declare no competing interests.
: The limited sample size constrained the statistical power and generalizability, especially for the uncommon SNPs and rare alleles detected in this study.
